AACR 2023 | Increasing the use of tissue-agnostic treatments in patients

Mohamed Gouda, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the utility and future of tissue-agnostic therapies. The genetic alterations associated with tissue-agnostic treatments have found to be relatively common, where 15-20% of patients have a high tumor mutational burden, 3% have BRAF V600E mutations, and 1.5% have NTRK/RET fusions. Increasing testing in patients will enable them to have more potential treatment options. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.